ReviewWorld journal of gastroenterology2008
Stem cells for end stage liver disease: how far have we got?
Review in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis.The Korean journal of internal medicine · 2017Trial
- Pediatric Cholestasis: A Practical Approach to Histological Diagnosis.Diagnostics (Basel, Switzerland) · 2026Review
- Functional characterization of CD49fJournal of molecular histology · 2022Article
- Prednisolone and mesenchymal stem cell preloading protect liver cell migration and mitigate extracellular matrix modification in transplanted decellularized rat liver.Stem cell research & therapy · 2022Article
- Adult Stem Cell Therapy as Regenerative Medicine for End-Stage Liver Disease.Advances in experimental medicine and biology · 2022Article
- Overexpression of c-Met in bone marrow mesenchymal stem cells improves their effectiveness in homing and repair of acute liver failure.Stem cell research & therapy · 2017Article
- Therapeutic Potential of Bone Marrow-Derived Mesenchymal Stem Cells on Experimental Liver Injury Induced by Schistosoma mansoni: A Histological Study.International journal of stem cells · 2016Article
- SDF-1/CXCR4 Axis Promotes MSCs to Repair Liver Injury Partially through Trans-Differentiation and Fusion with Hepatocytes.Stem cells international · 2015Article
- Bone marrow derived stem cells for the treatment of end-stage liver disease.World journal of gastroenterology · 2014Review
- Ameliorative effect of bone marrow-derived stem cells on injured liver of mice infected with Schistosoma mansoni.The Korean journal of parasitology · 2014Article
- Human induced pluripotent stem cells derived hepatocytes: rising promise for disease modeling, drug development and cell therapy.Protein & cell · 2012Review
- Comparison of different methods for the isolation of mesenchymal stem cells from human umbilical cord Wharton's jelly.In vitro cellular & developmental biology. Animal · 2012Article
- A review on the therapeutic potential of embryonic and induced pluripotent stem cells in hepatic repair.Journal of natural science, biology, and medicine · 2011Article
- Use of stem cells for liver diseases-current scenario.Journal of clinical and experimental hepatology · 2011Review
- Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord.Stem cell reviews and reports · 2011Review
- Rescue of lethal hepatic failure by hepatized lymph nodes in mice.Gastroenterology · 2011Article
- Stem cell-based therapies for liver diseases: state of the art and new perspectives.Stem cells international · 2010Article
- Progress in stem cell-derived technologies for hepatocellular carcinoma.Stem cells and cloning : advances and applications · 2010Review
- Isolation of adipose and bone marrow mesenchymal stem cells using CD29 and CD90 modifies their capacity for osteogenic and adipogenic differentiation.Journal of tissue engineeringArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
End stage liver disease (ESLD) is a health problem worldwide. Liver transplantation is currently the only effective therapy, but its many drawbacks include a shortage of donors, operative damage, risk of rejection and in some cases recidivism of the pre-transplant disease. These factors account for the recent growing interest in regenerative medicine. Experiments have sought to identify an optimal source of stem cells, sufficient to generate large amounts of hepatocytes to be used in bioartificial livers or injected in vivo to repair the diseased organ. This update aims to give non-stem cell specialists an overview of the results obtained to date in this fascinating field of biomedical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.